Seoulin Bioscience Co.Ltd (038070) — Cash Flow-to-Debt Ratio
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of ₩631.76 Million could theoretically repay 0% of its total liabilities (₩32.75 Billion) in one year. See Seoulin Bioscience Co.Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seoulin Bioscience Co.Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Seoulin Bioscience Co.Ltd across 13 annual periods. For the full cash flow conversion analysis, see Seoulin Bioscience Co.Ltd (038070) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year debt coverage analysis for Seoulin Bioscience Co.Ltd. Check Seoulin Bioscience Co.Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | ₩4.76 Billion | ₩32.75 Billion | ▲ +155.6% |
| 2024 | -0.26x | ₩-4.61 Billion | ₩17.63 Billion | ▼ -972.3% |
| 2023 | 0.03x | ₩930.57 Million | ₩31.04 Billion | ▲ +135.2% |
| 2022 | -0.09x | ₩-4.36 Billion | ₩51.08 Billion | ▼ -159.0% |
| 2021 | 0.14x | ₩8.92 Billion | ₩61.71 Billion | ▼ -28.1% |
| 2020 | 0.20x | ₩3.68 Billion | ₩18.33 Billion | ▼ -42.3% |
| 2019 | 0.35x | ₩7.32 Billion | ₩21.00 Billion | ▲ +45.3% |
| 2018 | 0.24x | ₩4.17 Billion | ₩17.39 Billion | ▲ +260.4% |
| 2017 | 0.07x | ₩1.30 Billion | ₩19.54 Billion | ▼ -56.8% |
| 2016 | 0.15x | ₩2.76 Billion | ₩17.87 Billion | ▼ -22.1% |
| 2015 | 0.20x | ₩4.12 Billion | ₩20.80 Billion | ▲ +27.0% |
| 2014 | 0.16x | ₩2.74 Billion | ₩17.57 Billion | ▼ -40.6% |
| 2013 | 0.26x | ₩4.94 Billion | ₩18.82 Billion | — |